Keshan Wang

Dr. Keshan Wang


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 January 2023 in Cancer Research
Verified
Journal Article
Closed access
PDF file
KWKeshan Wang
Keshan Wang
FMFen Ma
Fen Ma
SASeiji Arai
Seiji Arai
YWYun Wang
Yun Wang
AVAndreas Varkaris
Andreas Varkaris
SBSteven P. Balk
Steven P. Balk
Noncanonical Wnt signaling by WNT5a has oncogenic and tumor suppressive activities, but downstream pathways mediating these specific effects remain to be fully established. In a subset of prostate cancer organoid culture and xenograft models, inhibition of Wnt synthesis stimulated growth, whereas WNT5a or a WNT5a mimetic peptide (Foxy5) markedly suppressed tumor growth. WNT5a caused a ROR2-dependent decrease in YAP1 activity, which was associated with increased phosphorylation of MST1/2, LATS1, MOB1, and YAP1, indicating Hippo pathway activation. Deletion of MST1/2 abrogated the WNT5a response. WNT5a similarly activated Hippo in ROR2-expressing melanoma cells, whereas WNT5a in ROR2-negative cells suppressed Hippo. This suppression was associated with increased inhibitory phosphorylation of NF2/Merlin that was not observed in ROR2-expressing cells. WNT5a also increased mRNA encoding Hippo pathway components including MST1 and MST2 and was positively correlated with these components in prostate cancer clinical datasets. Conversely, ROR2 and WNT5a expression was stimulated by YAP1, and correlated with increased YAP1 activity in clinical datasets, revealing a WNT5a/ROR2 negative feedback loop to modulate YAP1 activity. Together these findings identify Hippo pathway activation as a mechanism that mediates the tumor suppressive effects of WNT5a and indicate that expression of ROR2 may be a predictive biomarker for responsiveness to WNT5a-mimetic drugs. Significance: WNT5a signaling through ROR2 activates the Hippo pathway to downregulate YAP1/TAZ activity and suppress tumor growth, identifying ROR2 as a potential biomarker to identify patients that could benefit from WNT5a-related agents.

1 October 2019 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
TXTianbo Xu
Tianbo Xu
HRHailong Ruan
Hailong Ruan
ZSZhengshuai Song
Zhengshuai Song
QCQi Cao
Qi Cao
KWKeshan Wang
Keshan Wang
XZXiaoping Zhang
Xiaoping Zhang
Clear cell renal cell carcinoma (ccRCC) is one of the most common malignancies in urinary system. However, there are still no reliable biomarkers for the diagnosis and prognosis of ccRCC. In this study, we aimed to screen candidate biomarkers and potential therapeutic targets for ccRCC. Differentially expressed genes (DEGs) were screened using NetworkAnalyst. Protein-protein interaction (PPI) network and weighted gene co-expression network analysis (WGCNA) were utilized to identify hub genes. Then, we assessed the prognostic and diagnostic values of hub genes to screen candidate biomarkers. Gene Set Enrichment Analysis (GSEA) was applied to reveal potential mechanisms of candidate biomarkers in ccRCC. Oncomine database and The Human Protein Atlas were used to verify the expression of candidate biomarkers online. In addition, qRT-PCR, Enzyme linked immunosorbent assay (ELISA) and Immunohistochemistry (IHC) assays were performed to validate the expression level of candidate biomarkers in ccRCC cells and tissues. A total of 771 genes were identified as DEGs. GO function analysis showed that DEGs were mostly enriched in excretion, apical part of cell and monovalent inorganic cation transmembrane transporter activity. KEGG pathway analysis demonstrated that DEGs were mostly involved in Neuroactive ligand-receptor interaction. After utilizing PPI network and WGCNA, nine genes (IFNG, CXCR3, PMCH, CD2, FASLG, CXCL13, CD8A, CD3D and GZMA) were identified as the hub genes. Moreover, survival analysis exhibited that high expression of CXCL13 predicted poor survival in both overall survival (OS) and disease free survival (DFS). The ROC curves indicated that CXCL13 could distinguish ccRCC samples from normal kidney samples. High expression of CXCL13 group was mostly associated with RB and MEL18 pathways by GSEA. Furthermore, qRT-PCR, ELISA and IHC results showed that the expression of CXCL13 was elevated in ccRCC. Our study illustrated that CXCL13 had good diagnostic and prognostic value, which may become a candidate biomarker and therapeutic target for ccRCC.

9 December 2025 in Journal of Nanobiotechnology
Verified
Journal Article
Open access
PDF file
YHYuyue Hou
Yuyue Hou
RWRuolin Wu
Ruolin Wu
YZYan Zhou
Yan Zhou
CYChenru Yin
Chenru Yin
YGYongkang Gai
Yongkang Gai
XXXiaotian Xia
Xiaotian Xia
Inflammatory diseases, including autoimmune, infectious, and metabolic disorders, remain major global health challenges due to their complex pathogenesis and limited therapeutic options. In recent years, bioinspired nanotechnology has emerged as a transformative approach in precision medicine. Among various strategies, macrophage membrane-coated nanoparticles (MΦ-NPs) have gained significant attention for their excellent biocompatibility, immune evasion, and lesion-targeting capabilities. This review systematically outlines the construction strategies, biological characteristics, and functional mechanisms of MΦ-NPs. It details the fabrication process, including core material design, macrophage membrane extraction and functionalization, and efficient membrane–core assembly. The current applications of MΦ-NPs in the diagnosis and treatment of non-tumor inflammatory diseases, such as bacterial and viral infections, rheumatoid arthritis, inflammatory bowel disease, atherosclerosis, and bone tissue repair are comprehensively reviewed. Special emphasis is placed on their unique behavior in inflammatory microenvironments, where they enable site-specific drug delivery, prolonged circulation, and immune modulation, offering innovative solutions to long-standing therapeutic challenges. Furthermore, we discuss the emerging hybrid membrane systems that integrate macrophage membranes with those of red blood cells, platelets, or tumor cells, enhancing both targeting and therapeutic performance. Despite promising preclinical results, challenges remain regarding large-scale production, clinical translation, and biosafety evaluation. By integrating insights from nanotechnology, immunology, and translational medicine, this review provides a comprehensive perspective on the design, functionality, and therapeutic frontiers of MΦ-NPs. Continued advances in biomimetic nanomedicine are expected to drive the development of next-generation anti-inflammatory therapies with high precision and minimal systemic toxicity. Graphical abstract

9 April 2024 in Biomaterials Science
Verified
Journal Article
Closed access
PDF file
ZDZirui Dong
Zirui Dong
KXKaming Xue
Kaming Xue
AVAnushikha Verma
Anushikha Verma
JSJian Shi
Jian Shi
ZWZhihao Wei
Zhihao Wei
XZXiaoping Zhang
Xiaoping Zhang
Prostate cancer (PCa) is a leading cause of cancer-related death in men, and most PCa patients treated with androgen deprivation therapy will progress to metastatic castration-resistant prostate cancer (mCRPC) due to the lack of efficient treatment. Recently, lots of research indicated that photothermal therapy (PTT) was a promising alternative that provided an accurate and efficient prostate cancer therapy. A photothermic agent (PTA) is a basic component of PPT and is divided into organic and inorganic PTAs. Besides, the combination of PTT and other therapies, such as photodynamic therapy (PDT), immunotherapy (IT), chemotherapy (CT), etc., provides an more efficient strategy for PCa therapy. Here, we introduce basic information about PTT and summarize the PTT treatment strategies for prostate cancer. Based on recent works, we think the combination of PPT and other therapies provides a novel possibility for PCa, especially CRPC clinical treatment.

3 June 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
CYChao Yang
Chao Yang
QFQingxiao Fang
Qingxiao Fang
MLMengyu Li
Mengyu Li
JZJin Zhang
Jin Zhang
RLRui Li
Rui Li
JHJihui Hao
Jihui Hao
Prime editing (PE) is a precise tool for introducing genetic mutations in eukaryotes. Extending the efficient editing scope and mitigating undesired byproducts are possible. We introduce reverse PE (rPE), a SpCas9-directed variant that enabled DNA editing at the 3′ direction of HNH-mediated nick site. The rPE leveraging nCas9-D10A and rPE gRNA targeting the 5′ direction of HNH-mediated nick site inscribes genetic alterations, achieving a reverse editing window and potentially high fidelity. HNH and reverse transcriptase engineered using protein language models in conjunction with La facilitate circular erPEmax and erPE7max, achieving editing efficiency up to 44.41% without nick gRNA or positive selection. Furthermore, our findings underscore the capability of rPE in inserting functionally enhanced variant (PIK3CD E527G) for cell therapy. By expanding the editing scope and enhancing genomic manipulability, rPE represents a meaningful advancement in prime editing, improving its utility for research and therapeutic applications.

28 May 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
AVAndreas Varkaris
Andreas Varkaris
KWKeshan Wang
Keshan Wang
MNMannan Nouri
Mannan Nouri
NKNina Kozlova
Nina Kozlova
DSDaniel R. Schmidt
Daniel R. Schmidt
SBSteven P. Balk
Steven P. Balk
BH3 mimetic drugs that inhibit BCL-2, BCL-XL, or MCL-1 have limited activity in solid tumors. Through assessment of xenograft-derived 3D prostate cancer models and cell lines we find that tumors with RB1 loss are sensitive to BCL-XL inhibition. In parallel, drug screening demonstrates that disruption of nucleotide pools by agents including thymidylate synthase inhibitors sensitizes to BCL-XL inhibition, together indicating that replication stress increases dependence on BCL-XL. Mechanistically we establish that replication stress sensitizes to BCL-XL inhibition through TP53/CDKN1A-dependent suppression of BIRC5 expression. Therapy with a BCL-2/BCL-XL inhibitor (navitoclax) in combination with thymidylate synthase inhibitors (raltitrexed or capecitabine) causes marked and prolonged tumor regression in prostate and breast cancer xenograft models. These findings indicate that BCL-XL inhibitors may be effective as single agents in a subset of solid tumors with RB1 loss, and that pharmacological induction of replication stress may be a broadly applicable approach for sensitizing to BCL-XL inhibitors.